IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Rish Pai  ¹     Gert De Hertogh  ²     Walter Reinisch  ³     Noam Harpaz  ⁴     Brian G. Feagan  ⁵     Noah Agada  ⁶     Paul Pollack     Lai Shan Chan     Marijana Protic     Fernando Magro  ^7    
1 Mayo Clinic, Indianapolis, United States
² University Hospitals Leuven, Leuven, Belgium
³ Medical University Vienna, Vienna, Austria
⁴ Icahn School of Medicine, New York, United States
⁵ Robarts Clinical Trials Inc., Ontario, Canada
⁶ Eli Lilly and Company, Indianapolis, United States
⁷ University of Porto, Porto, Portugal

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)